NMPA Greenlights IND Submission for Initial Clinical Trial Using HLX53 Anti-TIGIT Fc Fusion Protein in Conjunction with HANSIZHUANG and HANBEITAI for Early Treatment in Patients with Advanced or Metastatic Liver Cancer.

Vertex Pharmaceuticals reports advancements in its suzetrigine pain treatment program. Suzetrigine, also known as VX-548, is an oral NaV1.8 inhibitor that could be the first new painkiller class for acute and neuropathic pain in two decades.

Telomir Pharmaceuticals Reveals Promising Early Results for Anti-Aging Medication Telomir-1 at a Press Event in Washington, D.C.

Subcutaneous Ocrevus, by Genentech, Shows Almost Total Control of Clinical Relapses and Brain Lesions Over a Year in Progressive and Relapsing MS Cases.

Ventus Therapeutics Releases Findings of Phase 1 Study for VENT-02, an Innovative Oral Brain-Targeting NLRP3 Inhibitor.

Press Announcement: Latest 48-week stage 2 findings on frexalimab indicate promising consistent effectiveness in treating multiple sclerosis.

Alvotech and Teva have received FDA clearance in the U.S. for their product SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab).

Eloxx Pharmaceuticals, Inc. announced recent developments in their programs for ELX-02 and ZKN-013, highlighting the Orphan Drug Designation awarded to ELX-02.

In the TOPAZ-1 Phase III trial, the combination of Imfinzi and chemotherapy increased the three-year overall survival rate by twofold in patients with advanced biliary tract cancer.

Neurona Therapeutics Reports Encouraging Results from Its NRTX-1001 Cell Therapy Study in Adults Suffering from Drug-resistant Focal Epilepsy at the 2024 AAN Annual Meeting.

TransCode Therapeutics has received FDA approval to start a Phase 1/2 clinical trial of TTX-MC138 in patients with advanced solid tumors.

Latest findings from Novartis on Fabhalta® (iptacopan) reveal a notable and statistically significant decrease in proteinuria by 38.3% compared to placebo in individuals suffering from IgA nephropathy (IgAN).